Results 171 to 180 of about 16,343,665 (315)

Upscaled Synthesis of α‐ and β‐Peptides in a Continuous‐Flow Reactor Using Propylene Carbonate as an Eco‐Friendly Solvent

Chemistry–Methods, EarlyView.
A rapid and scalable continuous‐flow solid‐phase peptide synthesis technology, using eco‐friendly propylene carbonate (PC) as a solvent is developed. Achieving high yields and purity, it synthesized α‐peptides, β‐peptide foldamers, and α/β‐peptide chimeras.
Nikolett Varró, Beáta Mándityné Huszka, Eszter Erdei, András Mándoki, István M. Mándity   +4 more
wiley   +1 more source

Nordentatin Inhibits Neuroblastoma Cell Proliferation and Migration through Regulation of GSK-3 Pathway. [PDF]

Curr Issues Mol Biol, 2022
Boonyarat C, Boonput P, Tongloh N, Kaewamatawong R, Chaiwiwatrakul S, Yenjai C, Waiwut P.   +6 more
europepmc   +1 more source

AICAR positively regulate glycogen synthase activity and LDL receptor expression through Raf-1/MEK/p42/44MAPK/p90RSK/GSK-3 signaling cascade [PDF]

, 2007
Hsiang-Ming Wang, Sonya Mehta, Rishipal R. Bansode, Wei Huang, Kamal D. Mehta   +4 more
openalex   +1 more source

FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making

Clinical Pharmacology &Therapeutics, EarlyView.
Real‐World Evidence (RWE) is increasingly used in submissions to regulatory agencies and health technology assessment bodies (HTAbs) to support the efficacy and effectiveness of new medicines and indications. However, there is limited information on the RWE characteristics that impact its role in approval and reimbursement decisions.
Gianmario Candore, Claire Martin, Mack J. Mills, Annabel Suter, Anna Lloyd, Danitza Chavez‐Montoya, Diego Civitelli, Birgit Wolf, Paul Bolot, Juergen Wasem, Montse Soriano Gabarró, Panos G. Kanavos, Mark Sculpher   +12 more
wiley   +1 more source

Faculty Opinions recommendation of An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling.

, 2002
Christine E. Holt
openalex   +1 more source

38: Signaling of soluble FMS-like tyrosine kinase-1 (SFLT-1) via the GSK-3 pathway in cytotrophoblast cells demonstrates a link between preeclampsia and hypoxia [PDF]

, 2007
Alice Robinson, Suzy Davies, Laura L. Laidler, Sang-Joon Lee, Kimberly K. Leslie   +4 more
openalex   +1 more source

Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis

Clinical Pharmacology &Therapeutics, EarlyView.
The objective of this modeling and simulation analysis was to determine an intravenous (IV) secukinumab dosing regimen with steady‐state exposure within the ranges of the approved subcutaneous (SC) regimens (300 and 150 mg every 4 weeks [q4w]) and to predict the efficacy and safety of this IV regimen for patients with psoriatic arthritis (PsA) or axial
Thomas Dumortier, Guillermo Valenzuela, Melvin Churchill, Jelena Mijatovic, Gerard Bruin, Luminita Pricop, Hanno Richards, Didier Renard, Atul Singhal, Anshu Marathe   +9 more
wiley   +1 more source

Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Pemetrexed is a cornerstone in chemo(immunotherapy) of non‐small cell lung cancer and mesothelioma; however, it is contraindicated in patients with renal impairment due to severe toxicity concerns. Therefore, a large proportion of patients is withheld from effective chemo(immunotherapy).
Nikki de Rouw, Leila‐Sophie Otten, Mart P. Kicken, Berber Piet, Bonne Biesma, Bianca van Veggel, Christi M.J. Steendam, Ben van den Borne, Lizza E.L. Hendriks, Sander Croes, Anne‐Marie C. Dingemans, Daphne W. Dumoulin, Ron H.J. Mathijssen, Jacobus A. Burgers, Alwin D.R. Huitema, Hieronymus J. Derijks, Maarten J. Deenen, Michel M. van den Heuvel, Rob ter Heine   +18 more
wiley   +1 more source

Activation of -catenin signalling by GSK-3 inhibition increases P-glycoprotein expression in brain endothelial cells [PDF]

, 2008
Joseph C. Lim, Katarzyna Kania, Hasini C. Wijesuriya, Sangeeta Chawla, Jaswinder K. Sethi, Łukasz Pułaski, Ignacio A. Romero, P. O. Couraud, Babette B. Weksler, Stephen B. Hladky, Margery A. Barrand   +10 more
openalex   +1 more source

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier, Kevin A. Friede, Mary E. Plomondon, Kyung Min Lee, Zhenyu Lu, Tia Dinatale, Scott L. DuVall, Jason L. Vassy, Stephen W. Waldo, John H. Cleator, Thomas M. Maddox, Daniel J. Rader, Themistocles L. Assimes, Scott M. Damrauer, Philip S. Tsao, Kyong‐Mi Chang, Deepak Voora, Julie A. Lynch, Jay Giri, VA Million Veteran Program, Sony Tuteja   +20 more
wiley   +1 more source